Literature DB >> 9299537

The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma.

A Sawano1, T Takahashi, S Yamaguchi, M Shibuya.   

Abstract

Flt-1, a tyrosine kinase receptor for vascular endothelial growth factor (VEGF), plays important roles in the angiogenesis required for embryogenesis and in monocyte/macrophage migration. However, the signal transduction of Flt-1 is poorly understood due to its very weak tyrosine kinase activity. Therefore, we overexpressed Flt-1 in insect cells using the Baculovirus system in order to examine for autophosphorylation sites and association with adapter molecules such as phospholipase Cgamma-1 (PLCgamma). Tyr-1169 and Tyr-1213 on Flt-1 were found to be auto-phosphorylated, but only a phenylalanine mutant of Tyr-1169 strongly suppressed its association with PLCgamma. In Flt-1 overexpressing NIH3T3 cells, VEGF induced autophosphorylation of Flt-1, tyrosine-phosphorylation of PLCgamma and protein kinase C-dependent activation of MAP kinase. These results strongly suggest that Tyr-1169 on Flt-1 is a major binding site for PLCgamma and important for Flt-1 signal transduction within the cell. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299537     DOI: 10.1006/bbrc.1997.7327

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.

Authors:  Maryam Farzaneh Behelgardi; Saber Zahri; Zahra Gholami Shahvir; Farhad Mashayekhi; Laleh Mirzanejad; S Mohsen Asghari
Journal:  Mol Biol Rep       Date:  2020-02-18       Impact factor: 2.316

Review 2.  Vascular endothelial growth factor signaling in hypoxia and inflammation.

Authors:  S Ramakrishnan; Vidhu Anand; Sabita Roy
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-09       Impact factor: 4.147

3.  In vivo mechanisms of vascular endothelial growth factor-mediated increased hydraulic conductivity of Rana capillaries.

Authors:  T M Pocock; D O Bates
Journal:  J Physiol       Date:  2001-07-15       Impact factor: 5.182

4.  A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.

Authors:  Yazmin Odia; Joohee Sul; Joanna H Shih; Teri N Kreisl; John A Butman; Fabio M Iwamoto; Howard A Fine
Journal:  CNS Oncol       Date:  2016-02-10

5.  A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration.

Authors:  H Gille; J Kowalski; L Yu; H Chen; M T Pisabarro; T Davis-Smyth; N Ferrara
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

6.  Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding.

Authors:  Y Yu; J D Hulmes; M T Herley; R G Whitney; J W Crabb; J D Sato
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

7.  RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway.

Authors:  Feng Wang; Mai Yamauchi; Masashi Muramatsu; Tsuyoshi Osawa; Rika Tsuchida; Masabumi Shibuya
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

8.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

9.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.

Authors:  S Hiratsuka; O Minowa; J Kuno; T Noda; M Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.

Authors:  Yazmin Odia; Fabio M Iwamoto; Argirios Moustakas; Tyler J Fraum; Carlos A Salgado; Aiguo Li; Teri N Kreisl; Joohee Sul; John A Butman; Howard A Fine
Journal:  J Neurooncol       Date:  2015-12-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.